NOTCH2 — Notch receptor 2

The NOTCH2 gene acts like an instruction manual for making a protein that works as a receiver on the surface of your cells. This receiver picks up signals from neighboring cells, which helps your body decide what different cells should become as you grow and develop. It plays a very important role in forming many parts of the body before birth, including the liver, heart, kidneys, and bones, and continues to help maintain bone health and immune function after birth. When there is a change or mutation in the NOTCH2 gene, the receiver might not work properly. If the receiver is broken and cannot pick up signals (loss of function), it can lead to Alagille syndrome, a condition that can affect the liver, heart, and other organs. On the other hand, if the mutation causes the receiver to stay turned on all the time (gain of function), it can lead to Hajdu-Cheney syndrome, which primarily causes severe bone problems like bone loss in the hands and feet. Understanding these changes helps doctors know how to best manage and treat the specific symptoms a patient might experience.

Gene description: The NOTCH2 gene provides instructions for making a transmembrane receptor protein that is a key component of the Notch signaling pathway. This pathway is essential for regulating cell-fate determination and the normal embryonic development of various organs, including the heart, liver, kidneys, and bones.

Patient and family guide: The NOTCH2 gene acts like an instruction manual for making a protein that works as a receiver on the surface of your cells. This receiver picks up signals from neighboring cells, which helps your body decide what different cells should become as you grow and develop. It plays a very important role in forming many parts of the body before birth, including the liver, heart, kidneys, and bones, and continues to help maintain bone health and immune function after birth. When there is a change or mutation in the NOTCH2 gene, the receiver might not work properly. If the receiver is broken and cannot pick up signals (loss of function), it can lead to Alagille syndrome, a condition that can affect the liver, heart, and other organs. On the other hand, if the mutation causes the receiver to stay turned on all the time (gain of function), it can lead to Hajdu-Cheney syndrome, which primarily causes severe bone problems like bone loss in the hands and feet. Understanding these changes helps doctors know how to best manage and treat the specific symptoms a patient might experience.

Gene function: The NOTCH2 protein functions as a receptor for membrane-bound ligands, such as Jagged-1, Jagged-2, and Delta-1. Upon ligand binding, the receptor is cleaved, releasing an intracellular domain that translocates to the nucleus to regulate the transcription of target genes involved in cell differentiation, proliferation, and apoptosis.

Protein structure: NOTCH2 is a single-pass Type 1 transmembrane protein. It consists of a large extracellular domain with multiple epidermal growth factor-like (EGF) repeats for ligand binding, a transmembrane region, and an intracellular domain containing Ankyrin repeats and a terminal PEST domain for signal propagation and regulation.

Molecular function: NOTCH2 acts as a critical mediator of intercellular communication by functioning as a transmembrane receptor. When its extracellular domain binds to specific ligands (Jagged and Delta families) on adjacent cells, it undergoes proteolytic cleavages by ADAM proteases and the gamma-secretase complex. This releases the Notch intracellular domain (NICD), which translocates into the nucleus. Inside the nucleus, the NICD interacts with DNA-binding proteins to form a transcriptional activation complex, thereby regulating the expression of target genes that control cell fate, differentiation, and tissue homeostasis during both embryonic development and adult life.

Mutation spectrum: The mutation spectrum of NOTCH2 includes missense, nonsense, frameshift, and splice site mutations. In Alagille syndrome, mutations are predominantly missense, but also include nonsense and splice site variants throughout the gene. In Hajdu-Cheney syndrome, mutations are specifically truncating (nonsense or frameshift) and localized to the terminal exon (exon 34).

Clinical significance: Mutations in NOTCH2 cause disease through both loss-of-function and gain-of-function mechanisms. Loss-of-function mutations, typically missense or truncating variants, disrupt normal Notch signaling and are associated with Alagille syndrome, leading to developmental defects in the liver, heart, and other organs. Conversely, gain-of-function mutations, specifically truncating mutations in the terminal exon (exon 34) that remove the PEST domain, prevent receptor degradation and cause Hajdu-Cheney syndrome, characterized by severe skeletal abnormalities like acro-osteolysis and osteoporosis. Somatic gain-of-function mutations are also implicated in certain cancers, such as marginal zone lymphoma, by promoting uncontrolled cell growth.

Inheritance: Autosomal Dominant

Chromosomal location: 1p12

Research and therapeutic approaches: Therapeutic approaches targeting NOTCH2 primarily focus on modulating the Notch signaling pathway. Gamma-secretase inhibitors (GSIs) are being explored to block the cleavage and activation of the Notch receptor, particularly in cancers driven by NOTCH2 gain-of-function mutations. Additionally, monoclonal antibodies specifically targeting the NOTCH2 receptor or its ligands are under investigation to inhibit excessive signaling. For conditions like Hajdu-Cheney syndrome, antiresorptive therapies (such as bisphosphonates) are used to manage bone loss, though specific gene therapies directly correcting NOTCH2 mutations are not yet standard clinical practice.